• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Int J Mol Sci. 2022 Sep 22;23(19):11174. doi: 10.3390/ijms231911174.ABSTRACTIncreased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group wit...
Source: Atherosclerosis - October 14, 2022 Category: Cardiology Authors: Viorel I Suica Elena Uyy Luminita Ivan Raluca M Boteanu Aurel Cerveanu-Hogas Rune Hansen Felicia Antohe Source Type: research

Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats.
CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases. PMID: 31852645 [PubMed - in process]
Source: Journal of Southern Medical University - November 29, 2019 Category: Universities & Medical Training Authors: Yinjuan T, Jianjun W, Yinglu G, Weijun C, Weijun T, Mingying L Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research